Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense® HER2 nanoparticle formulation under Good Manufacturing Practice (GMP) conditions has proceeded uninterrupted by the pandemic and has been completed on time. The second phase of manufacturing the nanoparticle material is expected to continue on schedule as the Company makes ready for its first human study.
Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study
August 21, 2025
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks